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Suppressive effects of fish oil on mesangial cell proliferation Recent studies have shown that dietary supplementa-
in vitro and in vivo. tion with v3 polyunsaturated fatty acids (v3 PUFAs)
Background. Mesangial cell proliferation is a characteristic retards disease progression in human and experimentalfeature of IgA nephropathy and many other forms of glomeru-
renal disease [1]. Fish and marine oils, including eicosa-lonephritis. Recent clinical studies have shown that dietary
pentaenoic acid (EPA, C20:5v3) and docosahexaenoicfish oil supplementation retards renal disease progression in
patients with IgA nephropathy. The mechanism by which this acid (DHA, C22:6v3), are abundant sources of v3 PUFA
effect occurs is unknown. [2, 3]. Administration of v3 PUFA was shown to reduce
Methods. The anti-Thy 1.1 (ATS) model of mesangial prolif-
proteinuria and ameliorate renal injury in murine lupuserative glomerulonephritis was employed to test the hypothesis
nephritis, experimental focal segmental glomerulosclero-that dietary fish oil supplementation reduces mesangial cell
proliferation following acute injury. Subcultured rat mesangial sis, and other types of renal diseases [4–8]. In IgA nephrop-
cells were used to determine the in vitro effects of eicosapenta- athy, the most common glomerulonephritis worldwide,
enoic acid (EPA) and docosahexaenoic acid (DHA), the pri- renal disease progression was markedly reduced in pa-mary components of fish oil, on proliferation.
tients given a fish oil supplement containing EPA andResults. Following antithymocyte serum (ATS) administra-
DHA [9, 10]. In our recent study performed to identifytion, proteinuria was significantly decreased in animals treated
with fish oil compared with sesame oil-treated controls. In ATS clinical and histopathologic features predictive of ad-
rats given fish oil, there was less mesangial cell and matrix verse outcome in IgA nephropathy, we found that the
expansion, mesangiolysis, or basement membrane disruption total glomerular score, a semiquantitative index of prolif-(D% 5 240%). ATS rats receiving fish oil had less glomerular
eration of mesangial and other glomerular cells, inflam-cell proliferation (PCNA-D% 5 250%) and a reduction of
a-smooth muscle actin expression (D% 5 227%) by mesangial mation, and extracellular matrix deposition, emerged as
cells. In subcultured rat mesangial cells, DHA, but not EPA, an independent predictor of renal failure [11]. Since mes-
significantly inhibited proliferation. angial proliferation is a key feature of progressive IgA
Conclusions. Fish oil inhibits mesangial cell activation and
nephropathy and other renal diseases [12], we soughtproliferation in ATS glomerulonephritis, reduces proteinuria,
to determine whether v3 fatty acids acted primarily byand decreases histologic evidence of glomerular damage. In
vitro, the antiproliferative effects of fish oil are more likely inhibiting mesangial cell activation and proliferation.
related to the action of DHA. We suggest that orally adminis- While the beneficial effect of dietary fish oil is reason-
tered fish oil, or purified DHA, may have a suppressive effect ably well documented as a phenomenon, the mechanismin acute phases or relapses of glomerulopathies by inhibiting
by which disease manifestations are suppressed remainsactivation and proliferation of mesangial cells.
unknown. In particular, it is not known whether v3
PUFAs are incorporated into renal tissue and into mes-
angial cells, and whether v3 PUFAs act on mesangial
cells directly or by modulating extrarenal mechanisms.
†Deceased This information is crucial for the rational use and re-
finement of pharmacotherapy with fish oil and/or its com-Key words: Thy 1.1, glomerulonephritis, DHA, EPA, antithymocyte
serum, proteinuria, v3 polyunsaturated fatty acids. ponents for IgA nephropathy and other mesangial prolif-
erative glomerulonephropathies.Received for publication February 10, 1999
To address these problems, we used an experimentaland in revised form September 1, 1999
Accepted for publication October 11, 1999 model of mesangial proliferative glomerulonephritis in-
duced in rats with monoclonal or polyclonal antibodiesÓ 2000 by the International Society of Nephrology
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to the Thy-1.1 antigen. In this model, after antibody which each glomerulus was graded on a scale of 0 to 41
administration, an initial complement-dependent mesan- using the following criteria: 0 5 negative staining; 11 5
giolysis is followed by rapid proliferation of mesangial less than 25% positive staining per glomerulus; 21 5 25
cells [13, 14]. The mesangial cells acquire a “myofibro- to 50% positive staining per glomerulus; 31 5 50 to
blast” phenotype with de novo expression of a-smooth 75% positive staining per glomerulus; and 41 5 greater
muscle actin [15]. Similar phenotypic changes of mesan- than 75% positive staining per glomerulus [17]. These
gial cells have been identified in IgA nephropathy and scores are based on an analysis of 50 glomeruli in renal
other mesangial proliferative glomerular diseases [15, tissue obtained from each rat; the mean score from each
16]. We demonstrate that the v3 PUFAs in fish oil are animal was averaged to calculate the mean 6 SE for
rapidly and effectively taken up by mesangial cells in each experimental group.
culture and incorporated into plasma and renal tissue of A semiquantitative scoring system was employed to
treated rats, that fish oil significantly inhibits prolifera- assess glomerular histopathologic alterations. The extent
tion of cultured mesangial cells in vitro, and that fish oil of mesangial cell and/or matrix expansion was graded
reduces glomerular proliferation, a-smooth muscle actin according to the relative glomerular area involved using
expression, and proteinuria in antithymocyte serum ATS the following criteria: 0 5 normal glomerular cellularity
glomerulonephritis. with no significant mesangial matrix expansion; 11 5
mesangial cell and/or matrix expansion involving less
than 25% of glomerular area; 21 5 mesangial cellMETHODS
and/or matrix expansion involving 26 to 50% of glomeru-Experimental design
lar area; 31 5 mesangial cell and/or matrix expansion
Male Wistar rats (180 to 220 g) were maintained on involving 51 to 75% of glomerular area; and 41 5 diffuse
a normal chow diet prior to and during the experimental (greater than 75% of glomerular area) mesangial cell
period. As in our previous study [17], rats were housed and/or matrix expansion or a glomerulus containing base-
in individual metabolic cages two days prior to ATS ment membrane disruptions and/or mesangiolysis. A to-
administration (22, 21) and during the experimental tal of 50 glomerular profiles was analyzed in a blinded
period. Rats were given fish oil (extracted from Oma- fashion, and the mean glomerular scores from rats
core capsules, batch 50885-2, 1 g capsule) twice daily treated with fish oil were compared with those obtained
by gavage beginning on day 21 and continuing until from control rats (treated with olive oil or sesame oil).
sacrifice at day 5. This formulation of fish oil capsules
contains ethyl esters of EPA (47%) and DHA (37%), Fatty acid analysis
providing a daily dose of approximately 4.7 g/kg EPA
Lipids from plasma and renal cortical tissue samplesand 3.7 g/kg DHA. Control animals received an identical
from experimental and control rats were extracted withdose of sesame oil (rich in oleic and linoleic acids) or
chloroform/methanol (1/2 by volume) using a modifiedolive oil (containing predominantly oleic acid) in the
method of Bligh and Dyer [18]. The phospholipid frac-same manner. On day 0, the ATS was injected intrave-
tion was isolated from the extracted lipids by thin-layernously. On days 21 and 3, the urinary excretion of pro-
chromatography in a neutral lipid solvent system (hep-tein for 24 hours was determined. At the end of the
tane/isopropylether/acetic acid, 60/40/2 by volume) [19]experiment on day 5, animals were anesthetized. The
using silica gel plates. Fatty acid methyl esters werekidneys were removed, and cortical biopsies were fixed
formed by the addition of 6% H2SO4 in methanol, andin methyl Carnoy’s solution.
transmethylation was performed at 808C for three hours
[20]. Following extraction of the dried fatty acid methylImmunostaining
esters using petroleum ether, the fatty acid methyl esterRenal tissue fixed in methyl Carnoy’s solution was
derivatives formed from the isolated phospholipid frac-embedded in paraffin and cut in 5 m sections. Renal
tion were analyzed by gas-liquid chromatography to de-histology was evaluated by routine periodic acid-Schiff
termine the fatty acid content using conditions similar(PAS) staining. To determine the number of proliferat-
to those described previously [20]. The composition foring cells, immunostaining for proliferating cell nuclear
individual fatty acids is reported as a percentage of totalantigen (PCNA) was performed as previously described
fatty acids present within the constituent phospholipid[11]. To determine the number of proliferating cells in
fraction.individual animals, 50 glomerular profiles from each re-
nal biopsy were analyzed, and positive staining was de-
Urine protein analysisfined as dark-brown nuclear staining. Immunoperoxi-
For determination of urinary protein, the urine col-dase staining for a-smooth muscle actin (monoclonal
lected in 24 hours was filtered, precipitated by 13% (finalantibody) was used to determine phenotypic change of
mesangial cells. A semiquantitative scale was used, in concentration) trichloroacetic acid (TCA), collected by
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centrifugation, and measured by the method of Lowry cultures treated with fatty acids were solubilized with
sodium dodecyl sulfate (SDS) and frozen for fatty acidet al [21].
analysis (discussed earlier in this article).
Preparation of albumin-bound free fatty acids, molar
ratio 0.7:1.0 FFA:albumin Lactate dehydrogenase assay
Culture supernatants from mesangial cells treated withFatty acids were resuspended in absolute ethanol and
slowly added to a 0.3 mmol/L solution of essential fatty AA, DHA, or EPA were isolated and assayed for lactate
dehydrogenase assay (LDH) activity by measuring theacid-free bovine serum albumin (BSA) in phosphate-
buffered saline (PBS), stirring under nitrogen for four reduction of pyruvate to lactate using a Sigma Diagnos-
tics kit (procedure #228-UV; St. Louis, MO, USA). LDHhours. Solutions were aliquoted and frozen. Final con-
centrations of the fatty acids in each preparation were activity was calculated from the change in 340 nm ab-
sorbance per minute and expressed per unit volume ofdetermined by gas-liquid chromatography using an inter-
nal standard fatty acid of known amount for quantitation. medium.
Complement-mediated cytotoxicity assayMesangial cell preparation and culture
Glomeruli were isolated from 200 g male Sprague- To determine whether fatty acid supplementation de-
creases ATS antibody binding or subsequent comple-Dawley rats by differential sieving, as previously de-
scribed [22–24]. Cell outgrowths were characterized as ment-mediated mesangiolysis, rat mesangial cells were
cultured in 24-well plates and treated with DHA, EPA,mesangial cells by positive immunohistochemical stain-
ing for vimentin, smooth muscle-specific actin, and nega- oleic acid, or linoleic acid, as described earlier in this
article. Cells were then given ATS (10 to 100 mL ATStive stains for cytokeratin, factor VIII-related antigen,
and leukocyte common antigen (antibodies from Dako antiserum) with rat complement (S-3394, 71 CH50 U/mL;
10 to 50 mL; Sigma Chemical Company). After sevenCorporation, Carpinteria, CA, USA). Cells used in ex-
periments were from passages 5 to 12. Mesangial cells hours, cellular cytotoxicity was assessed by LDH release
(LDH assay kit KG-1340K; Sigma Chemical Company).were plated in 150 mm culture dishes in complete Way-
mouth’s medium (Waymouth’s medium supplemented
Measurement of cAMP-dependent protein kinase Awith 20% heat-inactivated fetal calf serum), 15 mmol/L
activity in situHEPES, 1 mmol/L sodium pyruvate, 0.1 mmol/L nones-
sential amino acids, 2 mmol/L l-glutamine, 50 IU/mL We used a method described by Corbin [25] as in our
previous study [23], with minor modifications. Rats werepenicillin, 50 mg/mL streptomycin, and 1% ITS1 (insu-
lin, transferrin, selenium, and bovine serum albumin). treated for 72 hours with fish oil, 2 mL/day in two 1 mL
doses by gavage; controls received an identical dose of
[3H]-thymidine incorporation olive oil. Body weight was determined each day. After
the treatment period, glomeruli were isolated by differ-Rat mesangial cells were plated into 24-well culture
dishes at 5 3 104 cell/well and grown for 24 hours in ential sieving, as described earlier in this article. Glomer-
uli were split into two equal fractions and incubatedcomplete Waymouth’s medium. Twenty-four hours later,
cells were refed with Waymouth’s medium containing immediately after isolation either with or without IBMX
(0.5 mmol/L) at 358C for 30 minutes. Samples were then0.5% calf serum and supplemented with fatty acids (AA,
EPA, or DHA; 1 to 20 mmol/L). After 44 hours, cells frozen at 2708C. Glomeruli were homogenized in a me-
dium containing (final concentrations) 0.25 mol/L su-were treated with [methyl-3H]-thymidine (1 mCi/mL),
and cultures incubated for an additional four hours. crose, 0.5 mmol/L IBMX, 4 mmol/L ethylenediamine-
tetraacetic acid (EDTA), and 20 mmol/L MES-NaOHIn some experiments, platelet-derived growth factor
(PDGF; 1 to 5 ng/mL) was added 18 hours prior to buffer (pH 6.8). The homogenate was centrifuged at
27,000 3 g for 30 minutes at 0 to 48C. Protein concentra-addition of [methyl-3H]-thymidine, or indomethacin (10
mmol/L) was added one hour prior to DHA treatment. tion in the supernatants was determined by the method
of Lowry et al [21]. The protein kinase A (PKA) activityCells were washed twice with PBS and lysed by addition
of 0.2 N NaOH. After 20 minutes, the cell lysate was was measured in the supernatant by incorporation of
32-g-ATP into the oligopeptide Kemptide [25, 26]. Theneutralized with HCl. TCA was added to a final concen-
tration of 10%. The solution was passed over glass fiber glomerular extract was incubated in a mixture contain-
ing (final concentrations) 20 mmol/L MES-NaOH, 0.4disks (GF/C; Whatman, Clifton, NY, USA) and washed
twice with 10% TCA and once with 70% ethanol. Radio- mmol/L egtazic acid (EGTA), 0.1 mmol/L EDTA acid,
8 mmol/L NaF, 0.6 mg/mL BSA, and 160 mmol/L “Kemp-activity on the disks was determined by liquid scintilla-
tion counting. Incorporation of [3H]-thymidine was used tide” (LRRASLG; pH 6.8) either with or without 1
mmol/L added cAMP. The reaction was started by addi-as a measure of the rate of mitogenic synthesis of DNA.
Cell counts were obtained in parallel cultures. Additional tion of glomerular extract (2 mg protein per tube); the
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Table 1. Fatty acid compositions of plasma phospholipid ratsincubation was carried out for 10 minutes at 308C and
treated for five days with olive oil or fish oil
stopped by placing the incubation mixture on 2 3 2 cm2
Olive oil Fish oilphosphocellulose papers (Whatman P 81), which were
Standard Standardthen immersed immediately into 10 mmol/L Na4P2O7 in
Fatty acids Average deviation Average deviation1% H3PO4. The papers were then washed (3 3 15 min)
C16:0 22.8 1.2 22.9 0.6with 1% H3PO4 with constant agitation. The papers were
C18:0 22.4 2.2 21.9 0.6dried, and 32P radioactivity was determined by liquid
C20:0 0.1 0.1 0.3 0.0
scintillation counting. Autophosphorylation of glomeru- C22:0 0.5 0.1 0.5 0.1
C24:0 1.1 0.2 1.4 0.1lar extracts was negligible. The PKA activity was assayed
Sum saturated 46.9 3.0 47.0 0.6in 1 aliquot without added cAMP, another aliquot with
C18:1v9 12.4 2.7 7.0 0.4addition of 1 mmol/L cAMP (maximum stimulatory dose),
C20:1v9 0.5 0.5 1.0 0.2
and also in an aliquot with 1 mmol/L added cAMP plus C24:1v9 1.2 0.2 1.4 0.1
Sum monounsaturated 14.1 2.9 9.4 0.7maximum inhibitory dose (10 mmol/L) of a specific PKA
oligopeptide inhibitor WIPTIDE [26, 27]. The difference C18:2v6 16.0 2.7 10.8 1.3
C20:4v6 (AA) 13.9 1.4 14.6 1.0between PKA activity without and with 10 mmol/L WIP-
Sum v6 polyunsaturated 29.9 1.8 25.4 1.4TIDE was taken as specific PKA activity; the residual
C20:5v3 (EPA) 4.3 1.6 10.2 1.2protein kinase activity in the presence of WIPTIDE was
C22:5v3 1.0 0.3 1.6 0.5
subtracted. In situ activity of PKA was determined as a C22:6v3 (DHA) 3.7 0.4 6.6 0.7
Sum v3 polyunsaturated 9.1 1.4 18.3 1.6ratio of PKA activity measured without added cAMP
Totals 100.0 100.00(2cAMP) to total PKA activity measured with 1 mmol/L
cAMP (1cAMP) and expressed as (2cAMP/1cAMP) Data for each fatty acid are expressed as weight percent of total fatty acids
(N 5 6 in olive oil-treated and fish oil-treated groups).PKA activity ratio [25, 27].
Statistics
All analyses were performed in a blinded fashion using Biotech (Santa Cruz, CA, USA). Other reagents, all
coded samples. The identity of the samples was not re- of highest purity grades, were purchased from standard
vealed until analysis was complete. Results were evalu- suppliers.
ated by Student’s t-test for group or paired comparison;
P , 0.05 was considered statistically significant.
RESULTS
Materials
Fish oil increases v3 fatty acid levels in plasma and
Omacore fish oil capsules were obtained from Pro- renal tissue phospholipid isolated from treated rats
nova Biocare (Lysaker, Norway). Purified AA, DHA,
The data giving the fatty acid compositions of plasmaEPA, oleic acid, and linoleic acid were from Calbiochem
phospholipid from rats fed for three days with a diet(San Diego, CA, USA). ATS was kindly provided by
supplemented with fish oil or olive oil are shown in TableDr. Richard Johnson (University of Washington Medical
1. Results are expressed as percentage of total fatty acids.Center, Seattle, WA, USA). The Sigma Diagnostics lac-
Data for relevant v3 and v6 fatty acids are summarizedtate dehydrogenase kit was purchased from Sigma Chemi-
in Figure 1. Fish oil treatment significantly increasedcal Company. [methyl-3H]-thymidine (1 mCi/mL) was
total v3 fatty acid levels by two times (18.3% of totalpurchased from NEN Life Science Products, Inc. (Bos-
fatty acids vs. 9.1% in olive oil-treated controls, P ,ton, MA, USA). PKA inhibitor WIPTIDE and PKA
0.0001). Relative levels of EPA (C20:5v3) and DHAsubstrate Kemptide were purchased from Peninsula Lab-
(C22:6v3) were both significantly increased in plasma oforatories, Inc. (Belmont, CA, USA). Waymouth’s culture
fish oil-treated animals (10.2 vs. 4.3% for EPA, P ,medium was purchased from GIBCO BRL (Gaithers-
0.0001; 6.6 vs. 3.7% for DHA, P , 0.0001). Fish oilburg, MD, USA). Tissue culture plates were purchased
treatment did not affect relative proportions of plasma-from Corning Costar Corporation (Cambridge, MA,
saturated fatty acid levels, a most abundant class of fattyUSA). Tissue culture medium, heat-inactivated fetal calf
acids, whereas reduced proportions of monounsaturatedserum, HEPES, sodium pyruvate, and nonessential amino
(D% 5 235%) and v6 PUFA (D% 5 26%) levelsacids were purchased from GIBCO BRL. Glutamine,
were observed in fish oil-treated animals. Levels of AApenicillin, and streptomycin were purchased from Cell-
(C20:4v6) were similar in fish oil- and olive oil-treatedgro (Washington D.C., USA). ITS1 was obtained from
animals (14.6 vs. 13.9%, respectively).Collaborative Biomedical Products (Bedford, MA, USA).
Relative fatty acid levels in phospholipid from renalGlass fiber disks (GF/C) were obtained from Whatman
tissue extracted from fish oil-treated and olive oil-treatedInc. a-Smooth muscle actin antibody was obtained from
Dako. PCNA antibody was obtained from Santa Cruz rats are shown in Table 2. Data for relevant v3 and v6
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Fig. 2. Fatty acid compositions of renal tissue phospholipid obtainedFig. 1. Fatty acid compositions of plasma phospholipid from rats
from olive oil-treated ( ) and fish oil-treated (j) rats. Data are ex-treated for five days with olive oil ( ) or fish oil (j). Data are expressed
pressed as a percentage of total fatty acid composition for saturatedas a percentage of total fatty acids for saturated fatty acids, monounsa-
fatty acids, monounsaturated fatty acids, total v6 fatty acids, total v3turated fatty acids, total v6 fatty acids, total v3 fatty acids, AA, EPA,
fatty acids, AA, EPA, and DHA. Data represent the mean and standardand DHA. Data represent the mean and standard error of six animals
error of six animals per group and are from Table 2.per group and are from Table 1.
Table 2. Fatty acid compositions of renal tissue phospholipid from monounsaturated fatty acid levels were significantly de-
olive oil-treated and fish oil-treated rats creased in fish oil-treated rats (9.7 vs. 12.5%, P , 0.0032);
mean levels of v6 PUFA were lower in fish oil-treatedOlive oil Fish oil
rats compared with olive oil-treated rats, but this differ-Standard Standard
Fatty acids Average deviation Average deviation ence did not reach statistical significance. AA levels were
not different in renal tissue obtained from fish oil-treatedC16:0 22.0 1.6 21.7 1.8
C18:0 18.9 1.2 19.9 0.6 rats and olive oil-treated rats. There were no differences
C20:0 0.2 0.0 0.2 0.0 in unsaturated fatty acid levels between the two groups.
C22:0 0.6 0.0 0.6 0.0
These studies demonstrate that oral administration ofC24:0 3.4 0.3 3.4 0.3
Sum saturated 45.1 1.9 45.9 1.3 fish oil produces a relatively rapid change in plasma and
C18:1v9 10.4 1.4 7.9 0.9 renal tissue PUFA composition with enrichment of the
C20:1v9 0.3 0.1 0.2 0.0 phospholipid in v3 PUFA.
C24:1v9 1.8 0.2 1.6 0.1
Sum monounsaturated 12.5 1.5 9.7 1.0
Dietary fish oil supplementation reduces proteinuria
C18:2v6 11.6 0.4 11.5 0.5 in the Thy-1 glomerulonephritis modelC20:2v6 0.3 0.1 0.3 0.1
C20:4v6 (AA) 24.5 1.1 23.7 0.8 During the course of the study, no animals showed
Sum v6 polyunsaturated 36.4 0.7 35.4 0.9 clinically adverse effects. At the end of the experiment
C20:5v3 (EPA) 1.6 0.5 3.6 0.5 (day 5), there were no significant differences in body
C22:5v3 0.8 0.2 1.1 0.3
weight between the fish oil-supplemented and sesameC22:6v3 (DHA) 3.6 0.4 4.3 0.8
Sum v3 polyunsaturated 6.0 0.9 9.0 1.0 oil-supplemented groups. Group 1 (control) rats were
Totals 100.00 100.00 fed a normal diet from days 22 to day 5. On day 0, this
group received nonimmune goat serum instead of ATS.Fatty acid analysis was performed on homogenates from renal cortex isolated
after five day treatment. Data are expressed as weight percent of total fatty acid Group 2 (sesame oil) was administered sesame oil by
composition of phospholipid (N 5 6 animals per group).
gavage from days 21 through 5, as described in the
Methods section. Group 3 received fish oil from days
21 through 5. The mean 24-hour urine protein excretion
for these three groups is shown in Figure 3 and representsfatty acids are summarized in Figure 2. Fish oil increased
the relative proportion of v3 fatty acids in renal extracts the mean of three independent experiments. Fish oil
supplementation reduced proteinuria by over 50% inobtained from fish oil-treated rats by 50% (9.0 vs. 6.0%,
P , 0.0002). Renal tissue EPA levels were significantly ATS-treated rats compared with rats treated with sesame
oil (P , 0.05).increased (3.6 vs. 1.6%, P , 0.0001). The increase in
DHA did not reach statistical significance. As in plasma, The mean protein excretion in ATS-treated animals
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merulus compared with animals given preimmune serum
(data not shown). In glomeruli of ATS rats receiving fish
oil, the number of PCNA positive cells was significantly
lower (D% 5 250%, P 5 0.001; Fig. 7) than in ATS-
injected rats given sesame oil.
In vitro studies
To determine whether fish oil directly affects mesan-
gial cell proliferation, in vitro studies were performed in
cultured rat mesangial cells. Rat mesangial cells were
plated in 24-well culture dishes at 5 3 104 cell/well and
grown for 24 hours. Cells were refed with Waymouth’s
Fig. 3. Dietary fish oil supplementation reduces proteinuria in ATS medium containing 0.5% fetal calf serum, and purified
glomerulonephritis. Urine protein excretion was assessed prior to ATS fatty acid-BSA preparations were added. [3H]-thymidine
administration (day 21; ) and at day 3 after ATS administration (j).
was added for the final four hours of a 48-hour incubation.Control animals did not receive ATS. Data represent the mean and
standard error of three independent experiments with N 5 4 to 6
animals per group in each experiment. In vitro fatty acid incorporation studies
There were no differences in saturated fatty acid com-
position among AA, EPA, and DHA-supplemented
mesangial cells (Table 3 and Fig. 8). Although the sumsgiven sesame oil (containing predominantly oleic and
of the v6 plus v3 PUFA were essentially constant acrosslinoleic acids), olive oil (containing predominantly oleic
the three treatments (ranging from 31.6 to 32.9%), theacid), or no dietary fatty acid supplementation was simi-
relative amounts of the long-chain PUFA (AA, EPA,lar (data not shown), providing support for the hypothe-
DHA) within these groups changed dramatically andsis that the protective effects of fish oil on proteinuria
directly reflected the corresponding supplemented long-in ATS-treated rats represent a specific effect of dietary
chain PUFA. For example, the AA-supplemented cells
v3 fatty acid supplementation.
showed 16.4% of total fatty acids as AA; these cells also
showed the lowest quantity of EPA at 1.0% and theHistologic studies
highest quantity of C22:4v6, which is an elongation prod-
Renal architecture evaluated by PAS stain at day 5
uct of AA.
from ATS-injected animals given sesame oil showed
With EPA supplementation, the EPA level increased
mesangial hypercellularity, focal mesangiolysis, and in- to 7.7% of total fatty acids and appeared to replace AA
creased frequency of mitotic figures with marked expan- such that the sum of AA plus EPA was almost identical
sion of extracellular matrix. Occasional tubules were di- to the AA level in the AA-supplemented cells. Further-
lated and filled with proteinaceous casts, but there were more, the added EPA was elongated to DPA (C22:5v3),
no significant interstitial inflammatory infiltrates or vas- which increased up to 6.8% of total fatty acids with
cular lesions identified. Glomeruli observed in PAS- supplementation, whereas the C22:4v6 showed a consid-
stained sections obtained from ATS-injected animals erable decrease (1.0%).
given fish oil had less mesangial cell and matrix expan- In the DHA-supplemented cells, DHA rose to 7.5%
sion (Fig. 4). Using a semiquantitative histologic scoring of total fatty acids and was accompanied by a markedly
system based on area of glomerular involvement, fish oil lowered level of AA (9.0%) relative to the AA-supple-
supplementation significantly reduced histologic mani- mented cells. Relative to AA-supplemented cells, EPA
festations of glomerular injury [mean histologic score in was significantly higher (at 4.0%), which is consistent
sesame oil-treated rats, 2.34 (6 SE); mean histologic with a metabolic retroconversion of DHA to EPA. This
score in fish oil-treated rats, 1.41 (6 SE); P 5 0.0005; retroconversion has been reported in isolated cells, animal
Fig. 5]. studies, and in human subjects receiving purified DHA.
a-Smooth muscle actin expression was evaluated, as
DHA inhibits [3H]-thymidine incorporation into DNAin our previous study [17]. Glomerular a-smooth muscle
by cultured mesangial cellsactin expression was significantly decreased in ATS rats
administered fish oil compared with sesame oil-treated [3H]-thymidine uptake was measured in cultured rat
controls (D% 5 27%, P 5 0.0004; Fig. 6). mesangial cells grown in Waymouth’s medium alone (con-
A quantitative evaluation of glomerular cell prolifera- trol) or in Waymouth’s medium supplemented with EPA
tion was performed using PCNA staining. In rats given or DHA. [3H]-thymidine uptake was significantly inhib-
sesame oil, ATS produced a greater than 15-fold increase ited in cultures given DHA in a dose-dependent fashion
(38% inhibition in cultures given 10 mmol/L DHA andin the number of PCNA-positive cells within each glo-
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Fig. 4. Representative histopathologic alter-
ations in ATS rats treated with fish oil or ses-
ame oil. (A) Glomerulus with minimal mesan-
gial cell or matrix expansion (histopathologic
score of 0 from a rat treated with fish oil;
PAS stain, original magnification 3200). (B)
Glomerulus with moderate mesangial cell and
matrix expansion (histopathologic score of 2
from a rat treated with fish oil; PAS stain,
original magnification 3200). (C) Glomerulus
with diffuse endocapillary proliferation, lead-
ing to severe compromise of capillary loop
lumens (histopathologic score of 4 from a rat
treated with sesame oil; PAS stain, original
magnification 3200).
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Fig. 7. Fish oil decreases PCNA expression by glomerular cells. Immu-Fig. 5. Dietary fish oil supplementation decreases the semiquantitative
nohistochemical staining of tissue sections obtained from rats treatedindex of glomerular injury in ATS nephritis. Fifty glomeruli were evalu-
with fish oil or sesame oil (controls) prior to ATS induction stained forated in PAS-stained sections obtained from ATS rats treated with fish
PCNA, a marker of proliferating cells. The total number of PCNAoil or sesame oil (controls). Data represent mean 6 SE from one
positive cells was counted in 50 glomeruli. Data represent the meanrepresentative experiment and equals six in each group.
number of positive cells per glomerulus 6 SE (N 5 6 for each group).
duces glomerular injury in vivo. The effects of DHA on
mesangial cell proliferation were then compared with
that of oleic acid and linoleic acid, the fatty acid compo-
nents of sesame oil or of olive oil, which were adminis-
tered as controls in the in vivo studies. [3H]-thymidine
uptake was measured in cultured rat mesangial cells
grown in medium supplemented with fatty acid-free BSA
(control) or BSA conjugates of DHA, oleic acid, or lino-
leic acid, as described in the Methods section. The inhibi-
tory effect of DHA on mesangial cell thymidine uptake
(246%) was significantly greater than that of linoleic
Fig. 6. Dietary fish oil supplementation decreases a-smooth muscle
acid (135%) or that of oleic acid (12%; Fig. 11).actin expression in ATS nephritis. Sections of renal cortex isolated from
rats treated with fish oil or sesame oil (controls) prior to ATS induction Lactate dehydrogenase assay release from cultured
were immunostained for a-smooth muscle actin, as described in the mesangial cells loaded with DHA, EPA, linoleic acid,
Methods section. Semiquantitative assessment of glomerular a-smooth
or oleic acid and treated with ATS and rat complementmuscle actin staining was performed on 50 glomeruli, as described in
the Methods section. Data represent the mean score 6 SE for six was similar (data not shown), indicating that the inhibi-
animals in each group. Data are representative of three independent tory effect of DHA on proliferation was not related toexperiments.
differences in the extent of initial complement-mediated
mesangial cell injury. The administration of indometha-
cin prior to DHA treatment produced a modest increase
67% inhibition in cultures given 20 mmol/L DHA, P , in 3H-thymidine incorporation (date not known). This
0.05). EPA treatment did not significantly alter thymi- increase, at least under these conditions, did not reach
dine uptake by cultured mesangial cells (Fig. 9). statistical significance, indicating that the inhibitory ef-
These differences in thymidine uptake were paralleled fect of DHA on mesangial proliferation is not solely due
by differences in cell number 48 hours after treatment. to perturbations in prostaglandin metabolism.
Total cell numbers in DHA-treated cultures were 37%
lower than those obtained in control cultures (P 5 Docosahexaenoic acid inhibits PDGF-mediated
0.00003). On the other hand, EPA did not significantly
thymidine uptake by cultured mesangial cells
alter mesangial cell number (Fig. 10). Differences in cell
A characteristic feature of IgA nephropathy and othernumber and thymidine uptake in DHA-treated cells
renal diseases is the growth factor or cytokine-mediatedwere not due to cytotoxicity; no appreciable release of
proliferation of mesangial cells. Since PDGF is a potentLDH into culture supernatants from cells treated with
mitogen for cultured mesangial cells and is expressed inDHA, EPA, or control cells was observed. These studies
proliferative renal diseases in vivo, we sought to deter-indicate that DHA is the component of fish oil that
inhibits proliferation of mesangial cells in vitro and re- mine whether DHA could block PDGF-induced mito-
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Table 3. Fatty acid enrichments of mesangial cell phospholipid following in vitro additions of AA, EPA, or DHA
Fatty acids Arachidonic acid (AA) Eicosapentaenoic acid (EPA) Docosahexaenoic acid (DHA)
C16:0 14.5 15.1 16.1
C18:0 19.3 20.2 20.1
C20:0 0.3 0.2 0.5
C22:0 0.4 0.3 0.7
C24:0 0.6 0.9 0.8
Sum saturated 39.2 40.7 40.7
C16:1v7 1.8 1.1 0.7
C18:1v9 23.0 21.9 22.6
C20:1v9 1.0 0.7 0.6
C22:1v9 0.5 0.4 0.3
C24:1v9 2.4 2.0 2.4
Sum monounsaturated 29.1 26.4 27.0
C18:2v6 5.0 5.5 5.7
C20:2v6 0.9 0.9 0.2
C20:3v6 2.1 2.0 2.6
C20:4v6 (AA) 16.4 7.5 9.0
C22:4v6 2.4 1.0 0.6
Sum v6 polyunsaturated 26.8 16.9 18.1
C18:4v3 0.3 0.4 0.2
C20:5v3 (EPA) 1.0 7.7 4.0
C22:5v3 2.4 6.8 2.5
C22:6v3 (DHA) 1.2 1.2 7.5
Sum v3 polyunsaturated 4.8 16.1 14.1
Totals 100.0 100.0 100.0
Results are presented as weight percent of total fatty acid composition of phospholipid. Minor fatty acids (including 14:0, 14:1, etc.) have been omitted from the
Table.
Fig. 9. DHA inhibits [3H]-thymidine uptake by cultured rat mesangial
cells. Cultured rat mesangial cells were treated with EPA or DHA priorFig. 8. Fatty acid enrichments of mesangial cell phospholipid following
to the assessment of [3H]-thymidine incorporation, as described in thein vitro additions of AA ( ), EPA (j), or DHA ( ). Results are
Methods section. Data represent the mean thymidine incorporation perexpressed as a weight percentage of total fatty acid composition of
well and are representative of six independent experiments.phospholipid.
ulated [3H]-thymidine uptake of mesangial cells growngenesis in cultured mesangial cells. Cultured rat mesan-
in fatty acid-free BSA (6.5-fold, P , 0.001; Fig. 12).gial cells were treated with DHA-BSA conjugate (20
The administration of DHA significantly reduced [3H]-mmol/L) or fatty acid-free BSA in culture medium sup-
thymidine uptake by PDGF-treated mesangial cellsplemented with 0.5% calf serum. Twenty-four hours prior
(257%, P , 0.002; Fig. 12). As previously shown, into the assessment of [3H]-thymidine uptake, cells were
the absence of PDGF treatment, DHA inhibited [3H]-treated with PDGF (5 ng/mL) or medium alone, as de-
scribed in the Methods section. As expected, PDGF stim- thymidine uptake (249%; Fig. 12).
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Fig. 10. DHA inhibits growth of cultured rat mesangial cells. Cell
counts were obtained from cultured rat mesangial cells treated with
Fig. 12. DHA inhibits platelet derived growth factor (PDGF)-medi-EPA, DHA, or the vehicle used to solubilize the fatty acids (control).
ated proliferation of cultured rat mesangial cells. Cultured rat mesangialData represent total cell number per well and are representative of six
cells were treated with DHA, as described in the Methods section.independent experiments.
Eighteen hours prior to assessment of [3H]-thymidine incorporation,
cultures were treated with PDGF (j; 20 mmol/L DHA) or vehicle
(control; ). Data represent mean thymidine incorporation per well
(N 5 3 to 4) and are representative of two independent experiments.
Fig. 13. Glomeruli were incubated without or with 0.5 mmol/L IBMX,
and in situ protein kinase A (PKA) activity was measured by determin-
ing (2cAMP/1cAMP) PKA activity ratio. The (2cAMP/1cAMP)Fig. 11. DHA inhibits thymidine uptake by cultured rat mesangial
PKA ratio in glomeruli from fish that were oil-treated (0.078 5 15,cells. Cultured rat mesangial cells were treated with DHA, oleic acid,
mean 1 SEM, N 5 7) did not differ from control glomeruli (0.81 5or linoleic acid prior to assessment of [3H]-thymidine incorporation,
17, mean 5 SEM, N 5 8). The increase (1D%) of PKA ratio in responseas described in the Methods section. Data represent mean thymidine
to IBMX was significantly higher in glomeruli from fish oil-treated ratsincorporation per well (N 5 3 to 4) and are representative of three
(right column) than in glomeruli from controls (left column).independent experiments.
mmol/L) was significantly higher in glomeruli from fishIn situ protein kinase A activation in isolated glomeruli
oil-treated rats than in glomeruli from olive oil-treated
Glomeruli isolated from fish oil-treated and olive oil- controls (P , 0.05; Fig. 13).
treated control rats were incubated without or with 0.5
mmol/L IBMX for 30 minutes at 358C, and in situ PKA
DISCUSSIONactivity was measured by determining (2cAMP/1cAMP)
the PKA activity ratio. In the absence of IBMX, the Recent studies have demonstrated that dietary fish
(2cAMP/1cAMP) PKA activity ratio in glomeruli from oil supplementation retards renal disease progression in
fish oil-treated rats did not significantly differ from glo- patients with IgA nephropathy [9, 10, 28]. However, the
meruli isolated from olive oil-control animals. However, mechanism through which fish oil exerts its protective
effect is not understood. Pathogenic components thatthe increase of PKA ratio in response to IBMX (0.5
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may be affected by fish oil therapy include proliferation mesangial cells can readily incorporate DHA (Table 3).
The changes in plasma and cellular lipid incorporationof glomerular cells, infiltration of inflammatory cells,
production of inflammatory mediators, and autocoids, elicited by fish oil feeding were reminiscent to findings
in humans. In humans with primary nephrotic syndrome,including arachidonic acid metabolites [29]. Since mesan-
gial cell proliferation is a central feature of IgA nephrop- six-week supplementation with fish oil produced in-
creases in platelet membrane EPA and DHA levels andathy, as well as many other forms of progressive glomeru-
lar diseases, we sought to test the hypothesis that fish oil an increased EPA:AA ratio [38]. In human subjects with
IgA nephropathy treated for one year, significant in-exerts its protective effect, at least in part, by inhibiting
mesangial cell proliferation. creases in v3 fatty acids, including EPA and DHA, were
associated with a significant reduction in plasma AAThe experiments were designed to test the effects of
exogenous fatty acid administration in addition to the levels [39].
In cultured rat mesangial cells, we demonstrate thatfatty acids provided by a basal chow diet. Control oils
for the ATS studies included olive oil, which contains EPA and DHA, the predominant v3 fatty acids compris-
ing fish oil concentrates, are readily incorporated intopredominantly oleic acid, and sesame oil, which contains
predominantly oleic acid and linoleic acid. Oleic acid mesangial cell phospholipid and metabolized. Both EPA
and DHA appeared to replace AA in treated mesangialethyl ester administration to Wistar rats does not alter
plasma and cell membrane fatty acid composition com- cells. These incorporation studies provide direct evi-
dence that cultured mesangial cells are capable of incor-pared with untreated animals [30]. As previously re-
ported in baseline studies, there is considerable variation porating v3 fatty acids into membrane phospholipid via
biosynthetic/acylation pathways.in the fatty acid composition of plasma phospholipids,
presumably reflecting differences in dietary intake [31– To our knowledge, the effects of v3 PUFA on mesan-
gial cell proliferation have not been previously exam-35]. Nevertheless, our observation that the plasma and
renal tissue phospholipids of rats treated with olive oil ined. Our experimental design allowed us to determine
whether fish oil or its fatty acid constituents directlycontain predominantly saturated fatty acids and v6 poly-
unsaturated acids with lesser amounts of monounsatur- affects mesangial cell proliferation, both in vivo and in
vitro. We demonstrate that in the anti-Thy-1.1 model ofated fatty acids and v3 PUFAs is similar to that reported
by other investigators [30]. mesangial proliferative glomerulonephritis, fish oil sup-
plementation significantly decreases components of glo-Fish oil, as administered to rats as 1 g capsules twice
daily by gavage for five days, significantly increased the merular injury, that is, mesangial cell and matrix expan-
sion. Glomerular cell proliferation, as measured byfraction of total v3 fatty acid levels, as well as EPA
and DHA, within plasma phospholipids, attesting that PCNA immunostaining, was significantly reduced by fish
oil therapy. In cultured mesangial cells, DHA did notPUFAs were adequately absorbed. This route of admin-
istration has been used in other studies to target v3 protect against complement-mediated mesangiolysis,
providing indirect evidence that the protective effect ofPUFAs to the kidneys and to other tissues [36].
Measures of EPA and DHA in serum/plasma phos- DHA on renal injury is due to inhibition of proliferation
rather than protection against the initial complement-pholipid have been considered to provide useful biologi-
cal indicators for EPA/DHA intake and nutritional sta- mediated injury following binding of ATS to the mesan-
gial cells. In addition, mesangial cell a-smooth muscletus [37]. The proportion of monounsaturated and v6
PUFA was decreased in the phospholipid, but AA levels actin expression, which reflects myofibroblast transfor-
mation, was significantly suppressed by fish oil therapy.did not change. Very similar alterations in fatty acid
levels were observed in the phospholipid of renal tissue These effects of fish oil are similar to those described in
human glomerular diseases such as IgA nephropathy [9].isolated from rats given fish oil; the proportion of total
v3 PUFA and EPA was significantly increased, with Our results show that DHA, but not EPA, both pre-
dominant components of fish oil, suppresses prolifera-decreases in the proportion of monounsaturated fatty
acids, thus indicating that v3 PUFAs were incorporated tion and growth of cultured mesangial cells. This finding
is consistent with a report that DHA inhibited prolifera-in target tissue. Although fish oil treatment rapidly in-
creased plasma phospholipid EPA and DHA content, tion of uterine stromal cells [40]. Proliferation of stromal
cells was not affected by cyclooxygenase, lipoxygenase,differences in DHA levels within renal tissue of fish oil-
fed animals and olive oil-fed controls, at least at the or cytochrome-P450 inhibitors, indicating that the inhibi-
tory effect of DHA is independent of eicosanoid biosyn-present dosage, did not reach statistical significance.
However, it should be considered that fatty acid incorpo- thesis [40]. Similarly, we have shown that indomethacin,
an inhibitor of prostaglandin synthesis, does not signifi-ration may not be quantitatively identical in all cell types
residing in renal cortex, which include glomerular cells, cantly alter 3H-thymidine uptake of DHA-treated rat
mesangial cells. In contrast to our findings in mesangialtubular epithelial cells, and interstitial cells. Results from
experiments in cultured mesangial cells demonstrate that cells, both EPA and DHA suppress proliferation of cul-
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tured vascular smooth muscle cells [41]. This difference vasodilatory, rather than vasoconstricting, properties [2].
One potential mechanism for the protective effect of fishmay be accounted for by the fact that higher doses of
both EPA and DHA were used (20 to 160 mmol/L) than oil may be through competition with AA as substrates
for products of the lipoxygenase and cyclooxygenasewere used in the current study.
While our studies document that DHA, and possibly pathways. For example, EPA is a substrate for prosta-
cyclin (PGI3), which has vasodilatory and platelet-antiag-other v3 PUFAs, inhibit mesangial cell proliferation, the
mechanism by which this occurs awaits clarification. In gregating properties akin to PGI2 [42]. Prostacyclins are
also potent agonists of glomerular adenylate cyclase.our previous studies, we observed that activation of the
cAMP-PKA signaling pathway, due to inhibition of EPA is also a substrate for thromboxane-A3, which un-
like thromboxane-A2, has little or no vasoconstricting orcAMP hydrolysis by phosphodiesterase (PDE) inhibi-
tors [23] or activation by adenylate cyclase agonists [23], platelet-aggregating properties [43]. In the kidney, when
AA is a substrate for the cyclooxygenase pathway,causes suppression of mesangial cell proliferation in
vitro, as well as in the anti-Thy 1.1 glomerulonephritis thromboxane-A2 is generated, which produces intense
vasoconstriction and mesangial cell contraction [44, 45].model in vivo. Since PUFA can be converted to powerful
agonists of adenylate cyclase such as prostacyclins and EPA is also a preferred substrate for products of the
lipoxygenase pathway, leading to the production of another prostanoids, we examined whether such products
released from glomeruli of fish oil-fed rats may activate inactive leukotriene-B5 [46, 47]. When AA serves as a
substrate, leukotriene-B4 is produced, which is a potentthe cAMP-PKA pathway. We found that under condi-
tions in which the majority of PDE isozymes are inhibited chemotactic factor for leukocytes. Therefore, v3 PUFA,
by competing with AA, may reduce various manifesta-by IBMX, the in situ PKA activity is increased in glomer-
uli from fish oil-treated rats. This finding suggests that tions of mesangial cell activation. This notion may be
consistent with the finding of a reciprocal relationshipactivation of cAMP-PKA may be a component of the
mechanism by which mitogenesis in mesangial cells is between AA and EPA or DHA (Table 3).
Fish oil-induced alterations in substrates for the lipox-suppressed; this possibility should be investigated in fu-
ture studies. ygenase and cyclooxygenase pathways have been ob-
served in renal injury models, including murine lupus,Fish oil treatment significantly reduced proteinuria
after the administration of ATS. The importance of this nephritis, or human nephrotic syndrome [48, 49].
In conclusion, using a well-defined model of acutefinding is underscored by observations that proteinuria is
one of the most sensitive and reliable markers of adverse mesangial proliferative glomerulonephritis and cultured
rat mesangial cells, we demonstrate that v3 fatty acidsoutcome in IgA nephropathy and other renal diseases.
The mechanism underlying the association between pro- are readily incorporated into renal cells, leading to de-
creased glomerular cell proliferation in vivo and in vitro.teinuria and mesangial cell proliferation is not clear. Our
current study, as well as previous observations of protein- The finding that DHA inhibits proliferation of cultured
rat mesangial cells indicates that v3 fatty acids may regu-uria in ATS glomerulonephritis, suggests that there may
be a relationship between glomerular proliferation and late proliferation in the absence of cytokines, growth
factors, or inflammatory mediators from other cell types.proteinuria. In a preliminary study, we found that the
administration of tyrophostin, a protein kinase inhibitor, Clarification of the cellular mechanism through which
dietary fish oil and its components suppress mesangialto ATS-treated rats decreases a-smooth muscle actin
expression by glomerular mesangial cells, but without cell activation and proliferation will provide the rationale
for the design of more targeted and effective pharmaco-any significant alterations in glomerular cell proliferation
or proteinuria (abstract; Thompson et al, J Am Soc therapy in treatment of mesangial proliferative glomeru-
lonephritis.Nephrol 6:856, 1995). On the other hand, the administra-
tion of PDE inhibitors ameliorates proteinuria, reduces
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